01 feb: Selskabsmeddelelse nr. 1/2017 - Regnskabsmeddelelse, Q1 2016/17
01 feb: Afholdt generalforsamling 2017
01-02-2017 12:00:45

Coloplast delivers satisfactory Q1 interim results in line with expectations

Relateret indhold
19 feb - 
Mandagens aktier: Defensiv nedtur for C25 trods plusser..
16 feb - 
Aktier/åbning: Nordea og DSV tager teten i grønt marked
15 feb - 
Torsdagens aktier: Novozymes og WDH toppede en positiv ..
Relateret debat
06 feb - 
sikke en styrke gad vide hvem der solgte i 474 idag, sk..
02 feb - 
Casen er altså intakt, har købt flere i pensionen, den ..
01 feb - 
Det har du sagt i lang tid. Men nej, USA går heller ikk..

In Q1, Coloplast delivered organic revenue growth of 6% and an EBIT margin of 33% at constant exchange rates. The results are in line with expectations.

Coloplast delivered organic growth of 6% in the first three months of the 2016/17 financial year, increasing revenue measured in Danish kroner by 3% to DKK 3,755m. EBIT increased by 3% to reach DKK 1,226m, while the profit for the period was up by 15% to DKK 946m.

Coloplast continued to generate growth in all business areas in the first quarter, delivering organic growth in Ostomy Care at 6%, Continence Care at 5%, Wound & Skin Care at 5% and Urology Care at 8%.

In Continence Care, Coloplast recently launched a new flexible catheter for men, the SpeediCath Flex. The product is now on the market in 11 countries. In addition, in Wound & Skin Care, the Biatain Silicone Sizes & Shapes product portfolio had been launched in eight countries on 1 January. Both launches have received very positive feedback from users and healthcare professionals.

Geographically, Europe was the main growth driver overall, delivering 6% organic growth, with sales growth in the UK and France standing out. Other developed markets produced 4% growth, while Emerging Markets contributed 7%.

"We delivered satisfactory results in the first quarter of the year, supported by a particularly strong performance of our European business. Growth in the US was affected by inventory reductions of large distributors. Inventory levels are now back to normal, and we expect this to drive favourable sales growth developments in the coming quarters," says Lars Rasmussen, CEO of Coloplast.

In a move to support the overall ambition of bringing innovative products and services to the US market, Coloplast acquired US distributor Comfort Medical in November. The acquisition was approved in late December, and the process of integrating the company has now been set in motion.

Coloplast continues to expect an organic revenue growth of 7-8% at constant exchange rates. Coloplast now expects organic revenue growth of 7-8% in Danish kroner (DKK) following the acquisition of Comfort Medical and developments in the British pound and the US dollar. Coloplast continues to expect the EBIT margin to be 33-34% at constant exchange rates and about 33% in DKK.

         Maria Lindeberg

         Senior Media Relations Manager

         +45 49 11 30 95

         dkmalg@coloplast.com

         

         Ellen Bjurgert

         Director, Investor Relations

         +45 49 11 33 76

         dkebj@coloplast.com

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Aktier/tendens: William Demant kan tage fokus i grøn åbning

23-02-2018 08:27:52
Der er udsigt til stigninger fredag morgen, når aktiemarkedet herhjemme åbner. Fra åbningen kan William Demant igen tage fokus, efter at selskabet har fået hævet kursmålet af en stribe finanshuse ovenpå torsdagens positive regnskab. I USA lukkede S&P 500 torsdagens handel med et plus på 0,2 pct., mens også Dow Jones lukkede med en gevinst på 0,7 pct. Til gengæld faldt Nasdaq med 0,1 pct. Futures f..

Aktier/middag: Genmab buldrer frem med WDH og ISS som følgesvende

22-02-2018 11:40:57
Biotekselskabet Genmab ligger helt i top i det danske eliteindeks torsdag middag efter at have præsenteret regnskab onsdag aften. Også ISS og William Demant, der begge kom med regnskab for fjerde kvartal torsdag morgen, er med i toppen.Men det er onsdagens regnskab fra Genmab, der trækker den helt store opmærksomhed, efter at biotekselskabet gjorde markedets bekymringer over en mulig skuffende pro..

ISS: Salget vokser mens bundlinjen skrumper

22-02-2018 08:39:00
ISS kan se bundlinjen falde tilbage i 2017 sammenlignet med i 2016, selvom selskabet er vokset på salget.Omsætningen i selskabet voksede til 79.912 mio. kr. i 2017, mens omsætningen udgjorde 78.658 mio. kr. i 2016.Omvendt steg nettoresultatet i 2017 til 2007 mio. kr. mod 2220 mio. kr. året før.Af regnskabet fremgår det, at årsagen til at bundlinjen ikke vokser med toplinjen, blandt andet er ekster..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Coloplast B A/S 525,40 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. februar 2018 22:44:53
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: ReleaseBuild_20180222.1 - EUROWEB2 - 2018-02-24 22:44:53 - 2018-02-24 22:44:53 - 1 - Website: OKAY